TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23773733
Drug: Histopathologic examination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histopathologic examination after fasudil injection
Study: 21118745
Drug: Generic test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic test formulation (3 tablets of 200 mg each)
Study: 21118745
Drug: Branded reference
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded reference formulation (1 tablet of 600 mg)
Study: 16377918
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with atorvastatin (20 mg/day) and colestimide (3 g/day)
Study: 16377918
Drug: Intensive monotherapy
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive monotherapy with atorvastatin (40 mg/day)
Study: 1875601
Drug: Nifedipine (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (routine drug dose tests at rest and during isometric and dynamic exercise)
Study: 1875601
Drug: Hydrochlorothiazide (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (routine drug dose tests at rest and during isometric and dynamic exercise)
Study: 6594492
Drug: Imipenem 10
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem 10 mg/kg
Study: 6594492
Drug: Imipenem 25
Normalized name: imipenem 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem 25 mg/kg
Study: 30701858
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow mesenchymal stromal cells (MSC) therapy (local and systemic administration)
Study: 30701858
Drug: Anticytokine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticytokine therapy with infliximab (IFX)
Study: 30701858
Drug: Antibiotic (AB)
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic (AB) and immunosuppressive (IS) therapy
Study: 27965998
Drug: Colchicine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1.0 mg per day for six weeks
Study: 20194916
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (alpha‐tocopherol 400 mg/day)
Study: 16610166
Drug: Hydroxymethylglutaryl coenzyme
Normalized name: Hydroxymethylglutaryl coenzyme A reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxymethylglutaryl coenzyme A reductase inhibitors (simvastatin) 10 mg/day plus diet (Group II)
Study: 10438046
Drug: HBV/MF59 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV/MF59 vaccine (2 or 3 immunizations)
Study: 10438046
Drug: HBV/MF59 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV/MF59 vaccine (2 doses, 2 months apart)
Study: 10438046
Drug: HBV/MF59 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV/MF59 vaccine (3 injections)
Study: 10438046
Drug: Licensed control
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed control vaccine (Recombivax HB)
Study: 10438046
Drug: HBV/MF59 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV/MF59 vaccine
Study: 7495044
Drug: Cilazapril 5
Normalized name: cilazapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 5 mg/day
Study: 2434792
Drug: Cilazapril (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (both doses)
Study: 380933
Drug: Neomycin ointment
Normalized name: neomycin Topical Ointment
DrugBank: Neomycin (DB00994)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neomycin ointment
Study: 31502945
Drug: internet-delivered dialectical
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-delivered dialectical behavior therapy (iDBT)
Study: 26919405
Drug: 96-hour ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 96-hour ketamine infusion (0.6 mg/kg/h target rate) with clonidine (max 0.6 mg orally daily)
Study: 26919405
Drug: 40-minute ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-minute ketamine infusion (0.5 mg/kg) with clonidine (max 0.6 mg orally daily)
Study: 23232195
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (50 mg daily for 2 weeks)
Study: 23232195
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) (200 micrograms twice daily for 10 weeks)
Study: 23232195
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (50 mg) and MFNS
Study: 23232195
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (50 mg)
Study: 21491823
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg orally once daily for 6 months (Group A)
Study: 21491823
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg vaginally once daily for 6 months (Group B)
Study: 17363838
Drug: 3-weekly combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-weekly combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone or cyclophosphamide, mitoxantrone, vincristine and prednisone (CNOP) chemotherapy with or without filgrastim
Study: 11908491
Drug: Cyclical sodium
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical sodium fluoride (NaF) 60 mg/day (6 months on, 3 months off) + calcium (1.0-1.2 g daily) + ergocalciferol (0.25 mg per 25 kg once weekly)
Study: 11908491
Drug: No sodium
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No sodium fluoride (NaF) + calcium (1.0-1.2 g daily) + ergocalciferol (0.25 mg per 25 kg once weekly)
Study: 30919782
Drug: Rifampin 300
Normalized name: rifampin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 300 mg/day
Study: 25367253
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy intervention including manual therapy and exercise or electrophysiological agents and exercise
Study: 24524874
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy intervention
Study: 24470716
Drug: 20mg oral
Normalized name: CLOBAZAM 20MG ORAL TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg oral isotretinoin once daily for 16 weeks
Study: 24470716
Drug: 20mg oral
Normalized name: CLOBAZAM 20MG ORAL TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg oral isotretinoin once daily along with 20% SA peels every two weeks for 16 weeks
Study: 16116336
Drug: Statins (simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (simvastatin or pravastatin, 10‐20 mg/d; atorvastatin, 5‐10 mg/d)
Study: 16116336
Drug: Control (soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (soy lecithin, 20 g/d)
Study: 10477838
Drug: Corticosteroid withdrawal
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid withdrawal from 10 to 5 mg of prednisone (n = 21)
Study: 10477838
Drug: Corticosteroid withdrawal
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid withdrawal from 5 to 0 mg of prednisone (n = 17)
Study: 10477838
Drug: 14-day prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day prednisone taper in 5 patients
Study: 7807035
Drug: Nebulized bacteriostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized bacteriostatic saline (3 mL, four times a day for 2 weeks)
Study: 7807035
Drug: Nebulized saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized saline (placebo) (3 mL, four times a day for 2 weeks)
Study: 7124593
Drug: Verapamil (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (0.075 and 0.15 mg/kg, not exceeding 10 mg per dose)
Study: 30219986
Drug: Citalopram 30
Normalized name: citalopram 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 30 mg
Study: 27777201
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of methylene blue and lidocaine plus oral valaciclovir (group A)
Study: 27777201
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of lidocaine plus oral valaciclovir (group B)
Study: 24161074
Drug: DASA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASA with or without concurrent aspirin
Study: 22742720
Drug: Alphacalcidol 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alphacalcidol 0.25 μg once daily for two weeks
Study: 22742720
Drug: Sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer carbonate 800 mg TID with meals for two weeks
Study: 19548438
Drug: Shenkangbao (SKB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenkangbao (SKB) at a dose of 10 g twice a day for 3 weeks
Study: 17611937
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (psychotherapy + pharmacotherapy)
Study: 15109971
Drug: Operant-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operant-behavioral treatment plus cognitive coping skills training
Study: 9655713
Drug: L-NAME 170
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME 170 mg
Study: 7640430
Drug: C2 samples
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C2 samples taken after slowing down blood flow rate (Qb) to 100 ml per min for 3 min (C2-100)
Study: 7640430
Drug: C2 samples
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C2 samples taken with Qb restored to 100 ml per min and the venous line clamped for 12 sec (C2-100-clamp)
Study: 7640430
Drug: C2 samples
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C2 samples taken after slowing down blood flow rate (Qb) to 50 ml per min for 3 min (C2-50)
Study: 7640430
Drug: C2 samples
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C2 samples taken with Qb slowed down to 50 ml per min and the venous line clamped (C2-50-clamp)
Study: 28784673
Drug: Finafloxacin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finafloxacin (single doses of 200 to 1,000 mg)
Study: 28784673
Drug: Finafloxacin (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finafloxacin (multiple doses of 600 to 1,000 mg)
Study: 26269239
Drug: Pakistani almonds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pakistani almonds (10 g/d)
Study: 26269239
Drug: American almonds
Approvals — FDA: no, EMA: no, PMDA: no
Description: American almonds (10 g/d)
Study: 24037607
Drug: Perceptual learning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceptual learning treatment for the amblyopic eye
Study: 15529479
Drug: No regular
Normalized name: Aveeno Regular Bath
Approvals — FDA: no, EMA: no, PMDA: no
Description: No regular daily activity
Study: 11573525
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 microg ml(‐1)
Study: 11573525
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 microg ml(‐1)
Study: 11573525
Drug: Propofol 4
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 4 microg ml(‐1)
Study: 11573525
Drug: Propofol 5
Normalized name: propofol 500 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 5 microg ml(‐1)
Study: 7823493
Drug: Sound vibration
Normalized name: VIBRATING DEVICE,CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sound vibration therapy with 2.5 kHz and 0.66 W/cm2 intensity
Study: 15767643
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once a day
Study: 2841742
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin 5000 IU t.d.s.
Study: 28625372
Drug: Subcutaneous implantable
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous implantable cardioverter defibrillator
Study: 25965706
Drug: Edoxaban (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (60 mg QD or 30 mg QD depending on factors)
Study: 25965706
Drug: Enoxaparin/warfarin followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin/warfarin followed by warfarin alone
Study: 29330461
Drug: C4 dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C4 dietary oil (10.7 g) plus 200 g carrot
Study: 29330461
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (19 g) plus 200 g carrot
Study: 29330461
Drug: Carrot (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrot (200 g)
Study: 20953791
Drug: GA 20
Normalized name: Potiga 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA 20 mg/0.5 mL (reduced volume formulation)
Study: 20953791
Drug: GA 20
Normalized name: Potiga 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA 20 mg/1.0 mL (marketed formulation)
Study: 16947012
Drug: Ifosfamide (IFS)
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide (IFS) with three doses of mesna
Study: 3100007
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg
Study: 2698566
Drug: Diltiazem 180
Normalized name: diltiazem 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 180 mg
Study: 7848788
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Diltiazem 120 mg + Enalapril 10 mg)
Study: 3057139
Drug: Antenatal steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal steroids (20 mg dexamethasone)
Study: 19926166
Drug: Routine antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antibiotics
Study: 796645
Drug: Ibuprofen (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1200 mg/day)
Study: 31800551
Drug: Mega dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mega dose corticosteroid (30 mg/kg stat and 15 mg/kg every 6 hours for 3 days)
Study: 28470106
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in neuropsychological test results during antipsychotic treatment
Study: 24850465
Drug: Fish-based diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-based diet (n-3 PUFAs ≧ 3.0 g/day)
Study: 22702523
Drug: Oral fidaxomicin
Normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral fidaxomicin for 10 days
Study: 3521518
Drug: Oral vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin
Study: 20034916
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with docetaxel combined with pirarubicin (TThp)
Study: 20034916
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with docetaxel combined with epirubicin (TE)
Study: 20034916
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (both regimens)
Study: 15076172
Drug: Conventional diuretic
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diuretic and/or beta-blocker therapy
Study: 10360293
Drug: Propranolol, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 40 mg, administered 1 hour prior to surgery
Study: 7731628
Drug: New therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New therapeutic options for conservative treatment of vulvar lichen sclerosus
Study: 466329
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment from qualified speech therapists
Study: 466329
Drug: Treatment from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment from non‐professional volunteers
Study: 31829912
Drug: Concurrent ADT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent ADT for 6 months starting simultaneously with RT
Study: 28938962
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral anticoagulants and antiplatelet drugs
Study: 25962329
Drug: Whole-body cooling
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body cooling (intermittent immersion in 14°C water until rectal temperature reached 35.5°C or for a maximum of 170 min)
Study: 23412808
Drug: Herbal/pharmaceutical supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal/pharmaceutical supplements
Study: 8780630
Drug: CT-RT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-RT group (cisplatin and vinblastine followed by radiation therapy)
Study: 8780630
Drug: RT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT group (radiation therapy alone)
Study: 23635728
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (500 mg, three times daily)
Study: 3938014
Drug: RMSF cases
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMSF cases (n=8, identified by direct fluorescent antibody technique)
Study: 31628016
Drug: Tumour Treating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumour Treating Fields (TTFields) at a frequency of 150 kHz delivered to the thorax in combination with intravenous pemetrexed (500 mg/m2 on day 1) and either cisplatin (75 mg/m2 on day 1) or carboplatin (AUC 5 on day 1) every 21 days for up to six cycles.
Study: 31628016
Drug: Tumour Treating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumour Treating Fields (TTFields) as maintenance treatment after chemotherapy.
Study: 31628016
Drug: Chemotherapy (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (pemetrexed and platinum) without TTFields.
Study: 26114588
Drug: Oxybutynin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin (2.5 mg per day, increased to 7.5 mg per day)
Study: 1587408
Drug: Intravenous cerulein
Normalized name: Sambucus nigra subsp. cerulea fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cerulein at doses of 30-60 ng/kg.h
Study: 1587408
Drug: 5 mg/kg.h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg.h loxiglumide with cerulein
Study: 1587408
Drug: 5 mg/kg.h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg.h loxiglumide with a meal
Study: 3884409
Drug: Piretanide tablet
Normalized name: piretanide
DrugBank: Piretanide (DB02925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide tablet
Study: 25074984
Drug: Testosterone-enanthate (TE)
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone-enanthate (TE) 125 mg/wk
Study: 23095425
Drug: Oral methylphenidate
Normalized name: methylphenidate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylphenidate stimulant medication
Study: 20124887
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (targeting normoglycemia, between 4.4 and 6.1 mmol/L)
Study: 20124887
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy (infusing insulin when blood glucose levels were >12 mmol/L and stopping at 10 mmol/L)
Study: 17393164
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel at a dose of 100 mg/m2 followed by carboplatin AUC 2, administered in blocks of six cycles with treatment-free intervals.
Study: 12469706
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) plus bisphosphonate
Study: 12469706
Drug: HRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT plus selective estrogen receptor modulator
Study: 12469706
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone (PTH) monotherapy
Study: 12469706
Drug: HRT alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT alone or in combination with bisphosphonate or PTH
Study: 10603129
Drug: Prolonged prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged prednisolone treatment (16 weeks)
Study: 10603129
Drug: Standard prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prednisolone treatment (8 weeks)
Study: 1770568
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous pethidine infusion (100 mg.24 h‐1)
Study: 1770568
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural pethidine infusion (100 mg.24 h‐1)
Study: 29176388
Drug: Citrulline Malate
Normalized name: CITRULLINE MALATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrulline Malate (8 g)